ω-carboxyl variants of 7-ketocholesteryl esters are ligands for β2-glycoprotein I and mediate antibody-dependent uptake of oxidized LDL by macrophages

Journal of Lipid Research

Volumn 43, Issue 9, 2002, Pages 1486-1495

  Liu, Qingping ^a   Kobayashi, Kazuko ^a   Furukawa, Jun Ichi ^b   Inagaki, Junko ^a   Sakairi, Nobuo ^b   Iwado, Akimasa ^c   Yasuda, Tatsuji ^a   Koike, Takao ^d   Voelker, Dennis R ^e   Matsuura, Eiji ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b HOKKAIDO UNIVERSITY   (Japan)

^c OKAYAMA UNIVERSITY   (Japan)

^d HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

Author keywords

Antiphospholipid syndrome; Atherosclerosis; Autoantibody; Oxidized LDL; 2 glycoprotein I; oxidation

Indexed keywords

7 OXOCHOLESTEROL; ACETONE; AUTOANTIBODY; BETA2 GLYCOPROTEIN 1; CARBOXYL GROUP; CHOLESTEROL ESTER; LAURIC ACID DERIVATIVE; LIPOSOME; OXIDIZED LOW DENSITY LIPOPROTEIN; 7-KETOCHOLESTEROL; ANTIBODY; CHOLESTEROL DERIVATIVE; GLYCOPROTEIN; LIGAND; LOW DENSITY LIPOPROTEIN;

ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; MACROPHAGE; METHYLATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT; CHEMICAL STRUCTURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOLOGY; METABOLISM; OXIDATION REDUCTION REACTION;

ANTIBODIES; BETA 2-GLYCOPROTEIN I; CHOLESTEROL ESTERS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; GLYCOPROTEINS; HUMANS; KETOCHOLESTEROLS; LIGANDS; LIPOPROTEINS, LDL; LIPOSOMES; MACROPHAGES; MOLECULAR STRUCTURE; OXIDATION-REDUCTION; PROTEIN BINDING;

EID: 0036737909     PISSN: 00222275     EISSN: None     Source Type: Journal    
DOI: 10.1194/jlr.M20063-JLR200     Document Type: Article

References (64)

1. Hughes, G. R. V., E. N. Harris, and A. E. Gharavi. 1986. The anti-cardiolipin syndrome. J. Rheumatol. 13: 486-489.
2. Harris, E. N., A. E. Gharavi, M. L. Boey, B. M. Patel, C. G. Mackworthyoung, S. Loizou, and G. R. V. Hughes. 1983. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet. 2: 1211-1214.
3. 2-glycoprotein I (apolipoprotein H). Proc. Natl. Acad. Sci. USA. 87: 4120-4124.
4. Galli, M., P. Comfurius, C. Maassen, H. C. Hemker, M. H. De Baets, P. J. C. Van Breda-Vriesman, T. Barbui, R. F. A. Zwaal, and E. M. Bevers. 1990. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet. 335: 1544-1547.
5. Matsuura, E., Y. Igarashi, M. Fujimoto, K. Ichikawa, and T. Koike. 1990. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet. 336: 177-178.
6. 2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface. J. Exp. Med. 179: 457-462.
7. Koike, T., A. Tsutsumi, K. Ichikawa, and E. Matsuura. 1995. Antigenic specificity of the "anticardiolipin" antibodies. Blood. 85: 2277-2278.
8. 2-glycoprotein I as an anti-cardiolipin cofactor determined using deleted mutants expressed by a baculovirus system. Blood. 87: 3262-3270.
9. 2-glycoprotein I is the antigen for anti-cardiolipin autoantibodies. Clin. Exp. Immunol. 115:571-576.
10. Wang, S. X., Y. T. Sun, and S. F. Sui. 2000. Membrane-induced conformational change in human apolipoprotein H. Biochem. J. 348: 103-106.
11. 2-glycoprotein I structure in the absence of phospholipid. Importance of Ag density and bivalent binding. J. Immunol. 154: 954-960.
12. 2-glycoprotein I and preserved during species' evolution. J. Immunol. 157: 5732-5738.
13. 2-glycoprotein I antibody affinity. J. Immunol. 161: 2038-2043.
14. 2-glycoprotein I antibody complexes. J. Biol. Chem. 276: 3060-3067.
15. 2-glycoprotein-I (apolipoprotein H) interactions with phospholipid vesicles. Int. J. Biochem. 16: 511-515.
16. Polz, E. 1988. Isolation of a Specific Lipid-Binding Protein from Human Serum By Affinity Chromatography Using Heparin-Sepharose. In Provides of Biological Fluids. H. Peeters, Editor. Pergamon Press, Oxford. 817-820.
17. 2-glycoprotein I and through it that of IgG antiphospholipid antibodies. Studies in platelets from patients with antiphospholipid syndrome and normal subjects. J. Autoimmun. 7: 335-348.
18. 2-glycoprotein I-dependent manner. J. Immunol. 157: 2201-2208.
19. 2-glycoprotein I to phospholipids based on its crystal structure. EMBOJ. 18: 5166-5174.
20. 2-glycoprotein I domain V by heteronuclear magnetic resonance. J. Mol. Biol. 304: 927-939.
21. 2-glycoprotein I domain V specifically interacts with hydrophobic ligands. Biochemistry. 40: 8092-8100.
22. 2-glycoprotein I). Biochem. Biophys. Res. Commun. 95: 1168-1172.
23. 2-glycoprotein-I to human serum lipoproteins. Distribution among density fractions. FEBS Lett. 102: 183-186.
24. 2-glycoprotein-I to intralipid: determination of the dissociation constant. Biochem. Biophys. Res. Commun. 90: 1305-1312.
25. Ross, R. 1986. The pathogenesis of atherosclerosis-an update. N. Engl. J. Med. 314: 488-500.
26. Ross, R. 1993. The pathogenesis of atherosclerosis: a perspecitive for the 1990s. Nature. 362: 801-809.
27. Palinski, W., M. E. Rosenfeld, S. Ylä-Herttuala, G. C. Gurtner, S. S. Socher, S. W. Butler, S. Parthasarathy, T. E. Carew, D. Steinberg, and J. L. Witztum. 1989. Low density lipoprotein undergoes oxidative modification in vivo. Proc. Natl. Acad. Sci. USA. 86: 1372-1376.
28. Ylä-Herttuala, S., W. Palinski, M. E. Rosenfeld, S. Parthasarathy, T. E. Carew, S. Butler, J. L. Witztum, and D. Steinberg. 1989. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J. Clin. Invest. 84: 1086-1095.
29. Penn, M. S., and G. M. Chisolm. 1994. Oxidized lipoproteins, altered cell function and atherossclerosis. Atherosclerosis. 108(Suppl.): 21-29.
30. Steinberg, D. 1995. Role of oxidized LDL and antioxidants in atherosclerosis. Adv. Exp. Med. Biol. 369: 39-48.
31. Vaarala, O., G. Alfthan, M. Jauhiainen, M. Leirisalo-Repo, K. Aho, and T. Palosuo. 1993. Crossreaction between antibodies to oxidised low-density lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet. 341: 923-925.
32. 2-glycoprotein-I and oxidized low-density lipoprotein in patients with antiphospholipid syndrome. Br. J. Rheumatol. 37: 746-749.
33. 2-glycoprotein I antibodies but not with antibodies against oxidized low-density lipoprotein. Br. J. Rheumatol. 37: 883-888.
34. 2-glycoprotein 1 and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages. Clin. Exp. Immunol. 107: 569-573.
35. 2-glycoprotein I mediates antoantibody-dependent uptake of oxidized low density lipoprotein by macrophages. J. Lipid Res. 42: 697-709.
36. Matsuura, E., Y. Igarashi, M. Fujimoto, K. Ichikawa, T. Suzuki, T. Sumida, T. Yasuda, and T. Koike. 1992. Heterogeneity of anticardiolipin antibodies defined by the anticardiolipin cofactor. J. Immunol. 148: 3885-3891.
37. Hashimoto, Y., M. Kawamura, K. Ichikawa, T. Suzuki, T. Sumida, S. Yoshida, E. Matsuura, S. Ikehara, and T. Koike. 1992. Anticardiolipin antibodies in NZW x BXSB FI mice. A model of antiphospholipid syndrome. J. Immunol. 149: 1063-1068.
38. 2-Glycoprotein I reactivity of monoclonal anticardiolipin antibodies from patients with the antiphospholipid syndrome. Arthritis Rheum. 37: 1453-1461.
39. Havel, R. J., H. A. Eder, and J. H. Bragdon. 1955. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J. Clin. Invest. 43: 1345-1353.
40. Ohkawa, H., N. Ohishi, and K. Yagi. 1979. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal. Biochem. 95: 351-358.
41. Folch, J., M. Lees, and G. H. Sloane-Stanley. 1957. A simple method for the isolation and purification of total lipids from animal tissues. J. Biol. Chem. 226: 497-509.
42. Nishikawa, K., H. Arai, and K. Inoue. 1990. Scavenger receptormediated uptake and metabolism of lipid vesicles containing acidic phospholipids by mouse peritoneal macrophages. J. Biol. Chem. 265: 5226-5231.
43. Kritharides, L., W. Jessup, J. Gifford, and R. T. Dean. 1993. A method for defining the stages of low-density lipoprotein oxidation by the separation of cholesterol- and cholesteryl ester-oxidation products using HPLC. Anal. Biochem. 213: 79-89.
44. Brown, M. S., S. K. Basu, J. R. Falck, Y. K. Ho, and J. L. Goldstein. 1980. The scavenger cell pathway for lipoprotein degradation: specificity of the binding site that mediates the uptake of negatively-charged LDL by macrophages. J. Supramol. Struct. 13: 67-81.
45. Brown, M. S., and J. L. Goldstein. 1983. Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis. Annu. Rev. Biochem. 52: 223-261.
46. Heinecke, J. W., L. Baker, H. Rosen, and A. Chait. 1986. Superoxide-mediated modification of low-density lipoprotein by arterial smooth muscle cells. J. Clin. Invest. 77: 757-761.
47. Parthasarathy, S., L. G. Fong, M. T. Quinn, and D. Steinberg. 1990. Oxidative modification of LDL: comparison between cell-mediated and copper-mediated modification. Eur. Heart J. 11 (Suppl. E): 83-87.
48. Lamb, D. J., and D. S. Leake. 1994. Acidic pH enables caeruloplasmin to catalyse the modification of low-density lipoprotein. FEBS Lett. 338: 122-126.
49. Tribble, D. L., B. M. Chu, G. A. Levine, R. M. Krauss, and E. L. Gong. 1996. Selective resistance of LDL core lipids to iron-mediated oxidation. Implications for the biological properties of ironoxidized LDL. Arterioscler. Thromb. Vasc. Biol. 16: 1580-1587.
50. Kamido, H., A. Kuksis, L. Marai, and J. J. Myher. 1995. Lipid esterbound aldehydes among copper-catalyzed peroxidation products of human plasma lipoproteins. J. Lipid Res. 36: 1876-1886.
51. Hoppe, G., A. Ravandi, D. Herrera, A. Kuksis, and H. F. Hoff. 1997. Oxidation products of cholesteryl linoleate are resistant to hydrolysis in macrophages, form complexes with proteins, and are present in human atherosclerotic lesions. J. Lipid Res. 38: 1347-1360.
52. Zhang, H. F., H. J. K. Basra, and U. P. Steinbrecher. 1990. Effects of oxidatively modified LDL on cholesterol esterification in cultured macrophages. J. Lipid Res. 31: 1361-1369.
53. 2+ ions: identification of major products and their effects. Biochem. Biophys. Res. Commun. 176: 431-440.
54. Brown, A. J., R. T. Dean, and W. Jessup. 1996. Free and esterified oxysterol: formation during copper-oxidation of low density lipoprotein and uptake by macrophages. J. Lipid. Res. 37: 320-335.
55. Cader, A. A., F. M. Steinberg, T. Mazzone, and A. Chait. 1997. Mechanisms of enhanced macrophage apoE secretion by oxidized LDL. J. Lipid Res. 38: 981-991.
56. Kodama, T., M. Freeman, L. Rohrer, J. Zabrecky, P. Matsudaira, and M. Krieger. 1990. Type I macrophage scavenger receptor contains α-helical and collagen-like coiled coils. Nature. 343: 531-535.
57. Endemann, G., L. W. Stanton, K. S. Madden, C. M. Bryant, R. T. White, and A. A. Protter. 1993. CD36 is a receptor for oxidized low density lipoprotein. J. Biol. Chem. 268: 11811-11816.
58. Ramprasad, M. P., W. Fischer, J. L. Witztum, G. R. Sambrano, O. Quehenberger, and D. Steinberg. 1995. The 94- to 97-kDa mouse macrophage membrane protein that recognizes oxidized low density lipoprotein and PS-rich liposomes is identical to macrosialin, the mouse homologue of human CD68. Proc. Natl. Acad. Sci. USA. 92: 9580-9584.
59. Sawamura, T., N. Kume, T. Aoyama, H. Moriwaki, H. Hoshikawa, Y. Aiba, T. Tanaka, S. Miwa, Y. Katsura, T. Kita, and T. Masaki. 1997. An endothelial receptor for oxidized low-density lipoprotein. Nature. 386: 73-77.
60. Stanton, L. W., R. T. White, C. M. Bryant, A. A. Protter, and G. Endemann. 1992. A macrophage Fc receptor for IgG is also a receptor for oxidized low density lipoprotein. J. Biol. Chem. 267: 22446-22451.
61. Lopes-Virella, M. F., N. Binzafar, S. Rackley, A. Takei, M. La Via, and G. Virella. 1997. The uptake of LDL-IC by human macrophages: predominant involvement of the FcγRI receptor. Atherosclerosis. 135: 161-170.
62. Khoo, J. C., E. Miller, F. Pio, D. Steinberg, and J. L. Witztum. 1992. Monoclonal antibodies against LDL further enhance macrophage uptake of LDL aggregates. Arterioscler. Thromb. 12: 1258-1266.
63. Kiener, P. A., B. M. Rankin, P. M. Davis, S. A. Yocum, G. A. Warr, and R. I. Grove. 1995. Immune complexes of LDL induce atherogenic responses in human monocytic cells. Arterioscler. Thromb. Vasc. Biol. 15: 990-999.
64. Morganelli, P. M., R. A. Rogers, T. J. Kitzmiller, and A. Bergeron. 1995. Enhanced metabolism of LDL aggregates mediated by specific human monocyte IgG Fc receptors. J. Lipid Res. 36: 714- 724.